The increased exposure of neoantigens and expression of chemokines in tumor cells induced by radiotherapy may offer new avenues for CAR-NK therapy development, such as CARs targeting NKG2DL or overexpressing chemokine receptors (CXCR1, CXCR2, and CXCR4) through CAR design (117–120). Here, CXCR1 is linked to neoplasm.